DexCom, Inc.

DexCom's G7 15 Day wins Health Canada authorization, offering longer wear, high accuracy and smart features for adults with diabetes.

zacks.com - 2026-07-14 11:21:37

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM whi.

businesswire.com - 2026-07-13 16:45:00

[url="]DexCom, Inc.[/url] (NASDAQ: DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July

gurufocus.com - 2026-07-09 09:00:00

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.

businesswire.com - 2026-07-09 08:30:00

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-07-08 10:45:26

DexCom, Inc.  DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 performance and a robust international foothold are expected to contribute further.

zacks.com - 2026-07-06 15:36:19

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

prnewswire.com - 2026-07-03 12:27:00

DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes market. DXCM aims to expand CGM adoption to Type 2 non-insulin patients, but commercial uptake remains unproven despite positive clinical trial results. At 28x earnings, DXCM's valuation is not demanding, yet offers limited upside given execution risks and the need for evidence of new market penetration.

seekingalpha.com - 2026-07-02 02:10:16

DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it the stronger stock to watch now.

zacks.com - 2026-06-26 09:36:09

DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening its glucose insights push.

zacks.com - 2026-06-24 10:31:17

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h.

businesswire.com - 2026-06-23 09:00:00

The GLP-1 revolution is quietly continuing even as investor interest has moved on to more timely topics. One of the best ways to access the fast-growing weight loss drug space is via makers like Novo Nordisk NYSE: NVO or Eli Lilly NYSE: LLY, the leading companies responsible for developing and manufacturing products like Ozempic and Zepbound.

marketbeat.com - 2026-06-20 08:45:12

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

barrons.com - 2026-06-18 14:14:00

Until recently, it had been a lackluster year for the healthcare sector. From high medical utilization squeezing insurers to structural cost pressures and valuation hangovers, medical stocks stocks have lagged much of the broader market this year.

marketbeat.com - 2026-06-18 09:31:18

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.

zacks.com - 2026-06-16 10:56:14

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-06-16 10:46:09

The U.S. Food and Drug Administration said on Friday it has expanded the ​use of Dexcom's Stelo Glucose Biosensor ‌System to children with diabetes, making it the first over-the-counter continuous glucose monitor for pediatric use.

reuters.com - 2026-06-12 16:15:32

Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose sensors ​it bought from licensed distributors had been ‌slated for destruction, after the device maker warned some units were stolen during disposal and ​resold.

reuters.com - 2026-06-11 06:08:12

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-10 10:51:07

DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.

zacks.com - 2026-06-08 14:31:04

DexCom Inc. (NASDAQ:DXCM) stock is trading higher on Monday after the diabetes management company reported positive results from its CONNECT randomized controlled trial.

benzinga.com - 2026-06-08 14:15:02

[url="]DexCom, Inc.[/url] (NASDAQ: DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clini

gurufocus.com - 2026-06-06 15:00:00

Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type ​2 diabetes not using insulin, compared with routine care, according to ‌study results.

reuters.com - 2026-06-06 14:49:45

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of.

businesswire.com - 2026-06-06 14:45:00

Oura Ring's IPO looks like Peloton in 2020 - great product, dangerous price. Ten public wellness stocks own the real trade.

investorplace.com - 2026-06-05 00:00:00

DXCM banks on CGM market growth, expanding international demand and strong Q1 momentum, though competitive pressures remain a key risk.

zacks.com - 2026-06-04 15:10:14

DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line. Which strategy stands out?

fool.com - 2026-06-04 11:50:52

[url="]DexCom, Inc.[/url] (NASDAQ: DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment

gurufocus.com - 2026-06-04 10:00:00

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association's Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e.

businesswire.com - 2026-06-04 09:00:00

They have outpaced the S&P 500 over the past 10 years.

fool.com - 2026-06-02 15:00:00

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights.

businesswire.com - 2026-06-02 09:30:00

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-05-27 10:47:07

Health tech startup Signos announced a $20 million funding round and expanded its partnership with medical device giant Dexcom. Signos makes an AI-powered glucose monitoring system designed to help with healthy weight loss, the first of its kind to be cleared by the FDA in 2025.

cnbc.com - 2026-05-27 09:07:44

Medical device maker Dexcom said on Tuesday some of its glucose sensors ​slated for destruction were instead stolen and ‌sold, prompting the company to warn users not to use products from two affected lots.

reuters.com - 2026-05-26 10:47:39

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine part of the company's quality control process. Sensors identified.

businesswire.com - 2026-05-26 09:30:00

Dexcom (DXCM) is leveraging AI to drive operational efficiency and product innovation, positioning itself as a platform medical provider in CGM. DXCM achieved 300 basis points in operating margin improvement, with sustained cost savings and strong FCF margin outpacing healthcare equipment peers. Stelo CGM, built with Google AI, targets the large prediabetic market, offering significant customer base expansion potential without requiring a prescription.

seekingalpha.com - 2026-05-22 17:40:11

DexCom is now rated a 'Buy' as improved fundamentals and a 15% lower stock price present a more attractive entry. Q1/26 results showed 15% revenue growth, and 90.9% operating income growth and raised 2026 guidance for both revenue and margins. Key growth drivers include international expansion, increased U.S. coverage for type 2 diabetics, and a $1B share buyback in 2026.

seekingalpha.com - 2026-05-21 21:57:57

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-05-20 10:50:18

DexCom gains 5.6% after announcing plans to launch Dexcom Flex in Germany, expanding CGM access for Type 2 diabetes patients using basal insulin or oral meds.

zacks.com - 2026-05-19 11:58:05

DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults w

gurufocus.com - 2026-05-18 08:00:00

SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available in Germany soon. Dexcom Flex is made for people using basal insulin, oral medications or GLP-1 receptor agonists, expanding access to CGM technology for a broader Type 2 diabetes population. D.

businesswire.com - 2026-05-18 07:31:00

DexCom NASDAQ: DXCM used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and margin improvement.

marketbeat.com - 2026-05-16 09:09:17

DexCom Inc. (NASDAQ:DXCM) introduced new long-term financial targets during its 2026 Investor Day, outlining expectations for sustained revenue growth and stronger profitability through the end of the decade.

benzinga.com - 2026-05-15 13:41:19

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-05-15 10:41:23

Dow and Nasdaq futures have plunged over 400 points as investors suffer from a cooling tech sector and U.S.-China policy fatigue

schaeffersresearch.com - 2026-05-15 08:56:00

DexCom, Inc. (DXCM) Analyst/Investor Day Transcript

seekingalpha.com - 2026-05-14 22:00:43

Medical device maker DexCom said on Thursday it has agreed with activist ​investor Elliott Investment Management to add ‌two independent directors to the company's board and revamp a key board committee.

reuters.com - 2026-05-14 17:41:22

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. “We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosensing platforms,” said Jake Leach, Dexcom's president and CEO. “Today's a.

businesswire.com - 2026-05-14 16:02:00

Pre-Market Stock Futures: The futures are trading lower on Tuesday, but another week and another set of new highs for the S&P 500 and the Nasdaq, as AI fever overshadowed Iran's peace counteroffer dismissal on Monday. The stock market opened lower on the rejection of President Trump's peace offering, but buyers once again circled the... Here Are Tuesday's Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe's, Matador Resources, Toast and More

247wallst.com - 2026-05-12 07:54:21